Atherosclerosis determinants in renal disease: How much is homocysteine involved?

Nephrology Dialysis Transplantation

Volumn 31, Issue 6, 2016, Pages 860-863

  Perna, Alessandra F ^a   Ingrosso, Diego ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; FOLIC ACID; HOMOCYSTEINE; S ADENOSYLHOMOCYSTEINE;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; AMINO ACID URINE LEVEL; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; EPIGENETICS; FOLIC ACID DEFICIENCY; GLOMERULUS FILTRATION RATE; HOMOCYSTEINE BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; KIDNEY DISEASE; RISK FACTOR;

ATHEROSCLEROSIS; HOMOCYSTEINE; HUMANS; KIDNEY DISEASES; RISK FACTORS;

EID: 84975113200     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv409     Document Type: Note

References (27)

1. Vanholder R, Glorieux G. Introduction: uremic toxicity-state of the art 2015. Semin Nephrol 2014; 34: 8586
2. Matsushita K, Coresh J, Sang Y et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 2015; 3: 514-525
3. Matsushita K, van der Velde M, Astor BC et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative metaanalysis. Lancet 2010; 375: 2073-2081
4. Mozaffarian D, Benjamin EJ, Go AS et al. Heart disease and stroke statistics -2015 update. A report from the American Heart Association. Circulation 2015; 131: e29-e322
5. Shlipak MG, Fried LF, Cushman M et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 2005; 293: 1737-1745
6. Clarke R, Bennett DA, Parish S et al. Homocysteine and coronary heart disease: metaanalysis of MTHFR case-control studies, avoiding publication bias. PLoS Med 2012; 9: e1001177
7. Ingrosso D, Cimmino A, Perna AF et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 2003; 361: 1693-1699
8. Perna AF, Capasso R, Lombardi C et al. Hyperhomocysteinemia and macromolecule modifications in uremic patients. Clin Chem Lab Med 2005; 43: 1032-1038
9. Clarke R, Halsey J, Lewington S et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37485 individuals. Arch Intern Med 2010; 170: 1622-1631
10. Huo Y, Li J, Qin X et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA 2015; 313: 1325-1335
11. McCaddon A, Miller JW. Assessing the association between homocysteine and cognition: reflection on Bradford Hill, meta-analyses, and causality. Nutr Rev 2015; 73: 723-735
12. Smith DA, de Jager CA, Refsum H et al. Homocysteine lowering, B vitamins, and cognitive aging. Am J Clin Nutr 2015; 101: 415-416
13. Refsum H. The homocysteine theory: dead or alive? In: Abstract, 10th International Conference One Carbon Metabolism, Vitamins B and Homocysteine, 7-11 July 2015, Medical School, University of Lorraine, Nancy, France, p. 48
14. Jardine MJ, Kang A, Zoungas S et al. The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis. BMJ 2012; 344: e3533
15. Smith DE, Hornsta JM, Kok RM et al. Folic acid supplementation does not reduce intracellular homocysteine, and may disturb intracellular onecarbon metabolism. Clin Chem Lab Med 2013; 51: 1643-1650
16. Green TJ, Skeaff CM, McMahon JA et al. Homocysteine-lowering vitamins do not lower plasma S-adenosylhomocysteine in older people with elevated homocysteine concentrations. Br J Nutr 2010; 103: 1629-1634
17. Perna AF, Ingrosso D, De Santo NG et al. Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia. J Am Soc Nephrol 1997; 8: 1988-1905
18. Zawada AM, Rogacev KS, Hummel B et al. S-adenosylhomocysteine is associated with subclinical atherosclerosis and renal function in a cardiovascular low-risk population. Atherosclerosis 2014; 234: 17-22
19. Perna AF, Lanza D, Sepe I et al. Altered folate receptor 2 expression in uraemic patients on haemodialysis: implications for folate resistance. Nephrol Dial Transplant 2013; 28: 1214-1224
20. Kang A, Nigwekar SU, Perkovic V et al. Interventions for lowering plasma homocysteine levels in kidney transplant recipients. Cochrane Database Syst Rev 2015; 5: CD007910
21. Bostom AG. Homocysteine: 'expensive creatinine' or important modifiable risk factor for arteriosclerotic outcomes in renal transplant recipients? J Am Soc Nephrol 2000; 11: 149-151
22. Potter K, Hankey GJ, Green DJ et al. Homocysteine or renal impairment, which is the real cardiovascular risk factor? Arterioscler Thromb Vasc Biol 2008; 28: 1158-1164
23. Kielstein JT, Salpeter SR, Buckley NS et al.Twocardiovascular risk factors in one? Homocysteine and its relation to glomerular filtration rate. Ameta-analysis of 41 studies with 27,000 participants. Kidney Blood Press Res 2008; 31: 259-267
24. Garibotto G, SofiaA, Saffioti S et al. Inter-organ exchange of aminothiols in humans. Am J Physiol Endocrinol Metab 2003; 284: E757-E763
25. Refsum H, Helland S, Ueland PM. Radioenzymic determination of homocysteine in plasma and urine. Clin Chem 1985; 31: 624-628
26. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013; 382: 339-352
27. Tousoulis D, Kourkouti P, Antoniades C et al. Impact of folic acid administration in homocysteine levels, inflammation and in atherosclerotic plaque area in apoE deficient mice. Int J Cardiol 2014; 177: 696-697